Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06355531
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-03-26
Brief Title:
A Study to Assess the Efficacy Safety and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy PSP
Sponsor:
Ferrer Internacional SA
Organization:
Ferrer Internacional SA
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Phase 2 Study to Assess the Efficacy Safety and Pharmacokinetics of FNP-223 Oral Formulation to Slow the Disease Progression of Progressive Supranuclear Palsy PSP PROSPER
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale PSPRS over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None